Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of MGTA-145 in Renal Impairment
NCT04154670Phase 1Completed
- Sponsor
- Ensoma
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of MGTA-145 in sickle cell disease (SCD), multiple myeloma (MM), beta thalassemia and 1 more (3 arms), sponsored by Ensoma. Primary endpoint: Pharmacokinetics Biomarkers at 2 days. Started Nov 2019; status: completed.
02
Drugs
MGTA-145
03
Conditions
sickle cell disease (SCD)multiple myeloma (MM)beta thalassemiahematologic malignancy
Beyond the preview
Go deeper on NCT04154670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154670.